Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

COMy Virtual 2020 | Ultra high-risk myeloma

Graham Jackson • 16 May 2020
COMy Virtual 2020
Multiple Myeloma Antibodies Bortezomib Daratumumab Dexamethasone Lenalidomide Thalidomide Vorinostat

Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, discusses ultra high-risk disease, the associated genetic abnormalities and the ongoing research aiming to tackle this patient population. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Graham Jackson

Myeloma treatment updates: a UK perspective
Myeloma treatment updates: a UK perspective
Graham Jackson • 14 Jun 2022
The management of patients with lenalidomide-refractory multiple myeloma in the UK
1:00
The management of patients with lenalidomide-refractory multiple myeloma in the UK
Graham Jackson • 30 Jan 2025
Recent approvals and updates impacting myeloma treatment in the UK
1:45
Recent approvals and updates impacting myeloma treatment in the UK
Graham Jackson • 30 Jan 2025
Unmet needs that remain for patients with myeloma in the UK
1:19
Unmet needs that remain for patients with myeloma in the UK
Graham Jackson • 30 Jan 2025

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Graham Jackson • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Graham Jackson • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Graham Jackson • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Graham Jackson • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals